Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
36 hedge funds and large institutions have $33.1M invested in Turnstone Biologics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 2 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
2.96% more ownership
Funds ownership: 53.43% → 56.39% (+3%)
3% more funds holding
Funds holding: 35 → 36 (+1)
31% less capital invested
Capital invested by funds: $48M → $33.1M (-$14.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2.36M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$491K |
| 3 |
Barclays
London,
United Kingdom
|
+$303K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$156K |
| 5 |
BlackRock
New York
|
+$53.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.33M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$740K |
| 3 |
ZP
Zimmer Partners
New York
|
-$244K |
| 4 |
Two Sigma Investments
New York
|
-$171K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$141K |
TSBX Hedge Fund Activity: Q4 2023 in Review
36 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q4 2023, worth a combined $33.1M — down 31% from $48M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TSBX positions and 2 closed out — a net gain of 1 holder — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Bank of America, adding an estimated $2.36M. The largest seller was PFM Health Sciences, cutting an estimated $2.33M.
- 36 institutional investors held Turnstone Biologics (TSBX) as of Q4 2023, up from 35 in Q3 2023.
- Funds reported $33.1M of Turnstone Biologics stock for Q4 2023, down 31% quarter-over-quarter.
- 3 funds opened new Turnstone Biologics positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Turnstone Biologics buyer in Q4 2023 was Bank of America, an estimated $2.36M added.
- The largest Turnstone Biologics seller in Q4 2023 was PFM Health Sciences, an estimated $2.33M sold.
Based on aggregated 13F filings for Q4 2023.